These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 11314743)

  • 1. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy.
    Macchia PE; Bagattini M; Lupoli G; Vitale M; Vitale G; Fenzi G
    J Endocrinol Invest; 2001 Mar; 24(3):152-8. PubMed ID: 11314743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
    Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
    Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].
    Brauer VF; Scholz GH
    Med Klin (Munich); 2004 Feb; 99(2):71-6. PubMed ID: 14963657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
    De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
    Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
    Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves' ophthalmopathy.
    Ohtsuka K; Sato A; Kawaguchi S; Hashimoto M; Suzuki Y
    Jpn J Ophthalmol; 2002; 46(5):563-7. PubMed ID: 12457917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy.
    Ohtsuka K; Sato A; Kawaguchi S; Hashimoto M; Suzuki Y
    Am J Ophthalmol; 2003 Mar; 135(3):285-90. PubMed ID: 12614743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy.
    Zhu W; Ye L; Shen L; Jiao Q; Huang F; Han R; Zhang X; Wang S; Wang W; Ning G
    J Clin Endocrinol Metab; 2014 Jun; 99(6):1999-2007. PubMed ID: 24606088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of Graves' ophthalmopathy with intravenous high-dose steroid followed by orbital irradiation.
    Koshiyama H; Koh T; Fujiwara K; Hayakawa K; Shimbo S; Misaki T
    Thyroid; 1994; 4(4):409-13. PubMed ID: 7711503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of Graves' orbitopathy treatment with intravenous glucocorticoids on adrenal function.
    Ambroziak U; Bluszcz G; Bednarczuk T; Miśkiewicz P
    Endokrynol Pol; 2017; 68(4):430-433. PubMed ID: 28604944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.
    Kahaly GJ; Pitz S; Hommel G; Dittmar M
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5234-40. PubMed ID: 15998777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy.
    Baschieri L; Antonelli A; Nardi S; Alberti B; Lepri A; Canapicchi R; Fallahi P
    Thyroid; 1997 Aug; 7(4):579-85. PubMed ID: 9292946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
    Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
    Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids.
    Myśliwiec J; Kretowski A; Topolska J; Siewko K; Jakubczyk D; Szelachowska M; Mikita A; Kinalska I
    Horm Metab Res; 2001 Dec; 33(12):739-43. PubMed ID: 11753760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy.
    Kauppinen-Mäkelin R; Karma A; Leinonen E; Löyttyniemi E; Salonen O; Sane T; Setälä K; Viikari J; Heufelder A; Välimäki M
    Acta Ophthalmol Scand; 2002 Jun; 80(3):316-21. PubMed ID: 12059873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
    Wiersinga WM
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
    Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
    N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study.
    Ng CM; Yuen HK; Choi KL; Chan MK; Yuen KT; Ng YW; Tiu SC
    Hong Kong Med J; 2005 Oct; 11(5):322-30. PubMed ID: 16219950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy.
    Kung AW; Michon J; Tai KS; Chan FL
    Thyroid; 1996 Oct; 6(5):381-4. PubMed ID: 8936659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.